We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
11.00 | 5.00% | 231.00 | 231.00 | 232.00 | 232.50 | 221.00 | 222.00 | 179,427 | 15:55:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.95 | 223.58M |
TIDMOXB
RNS Number : 6411C
Oxford Biomedica PLC
23 January 2018
Director Dealings / Market Share Purchase
Oxford, UK - 23 January 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Monday 22 January 2017 acquired ordinary shares in the Group as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.
Interest after purchase ----------- --------- ---------- ---------------- ---------------------------- Director Title Price Number of Number % of total / PDMR per share Ordinary Shares of Ordinary issued (p) acquired Shares share capital ----------- --------- ---------- ---------------- ------------ -------------- Dr Lorenzo Tallarigo Chairman 11.1p 23,941 2,197,028 0.07% ----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,107,704,224 ordinary 1p shares.
-Ends-
For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 John Dawson, Chief Executive 783 000 Officer Stuart Paynter, Chief Financial Officer Financial and corporate communications Tel: +44 (0)20 3709 enquiries: 5700 Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUOUKRWKAAURR
(END) Dow Jones Newswires
January 23, 2018 04:30 ET (09:30 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions